Spyryx Biosciences Receives Development Award from Cystic Fibrosis
Foundation Therapeutics to Advance Novel Therapy for CF
Durham, NC; June 25, 2015 – Spyryx Biosciences, Inc., a privately-held
biopharmaceutical company developing novel therapeutics for obstructive lung
diseases, announced today it has received an award from Cystic Fibrosis Foundation
Therapeutics, which will support development of Spyryx’ therapeutic peptides for
cystic fibrosis (CF).
“We appreciate the generous support of the Cystic Fibrosis Foundation and are
looking forward to working closely with them as we advance our program toward
clinical development,” stated John Taylor, President and CEO of Spyryx.
In the CF lung, the epithelial sodium channels (ENaC) hyperabsorb sodium and water
from the surface of the lung airway, leading to dehydration of the mucus layers and
reduced airway clearance. Spyryx is developing inhaled peptides, which are designed
to potently degrade ENaC, blocking this absorption and returning airway fluid
volumes to normal levels, with the goal of restoring proper mucociliary clearance.
This therapeutic approach is independent of the genetic mutations that cause the
disease and is anticipated to provide a treatment option to the entire CF patient
population. In preclinical models, Spyryx’ compounds have demonstrated robust
restoration of airway fluid volumes with a duration of action that may allow oncedaily
dosing in the clinic.
For more information about cystic fibrosis, go to www.cff.org.
About Spyryx Biosciences
Spyryx Biosciences is a biopharmaceutical company developing inhaled therapeutics
to address severe respiratory diseases via modulation of a novel biological
mechanism for regulating airway fluid. Founded in 2013, Spyryx’ lead program is
in pre-clinical development for cystic fibrosis. Further information regarding Spyryx
Biosciences is available at www.spyryxbio.com.
Spyryx Media Contact: